Articles tagged with Parkinsons Disease
Researchers found that deacetylase inhibitors can fully restore movement problems caused by the LRRK2 Parkinson's mutation in fruit flies. This study provides compelling evidence for a direct link between defective transport and movement problems, suggesting a potential therapy for people with this specific mutation.
The Braak hypothesis suggests that Parkinson's disease begins in the digestive tract and spreads to the brain. Researchers at Lund University have now found direct evidence of this process, tracking the spread of alpha-synuclein protein from the gut to the brain in rat models.
Researchers have made a groundbreaking discovery about the similarities and differences between two neurodegenerative diseases, progressive supranuclear palsy and Parkinson's Disease. The study reveals that individuals with PSP experience more severe cognitive impairments than those with PD early on.
Researchers at UCLA have discovered that the drug AT2101 improves motor function, stops inflammation, and reduces alpha-synuclein levels in mouse models of Parkinson's disease. This finding suggests that further investigation into the compound's potential for treating Parkinson's is warranted.
Researchers have observed a significant increase in Antarctic sea ice extent, reaching a new record high. This upward trend is an exception to the overall decline of sea ice globally.
University of Michigan scientists are launching a five-year effort to better understand the cause of falls in Parkinson's patients and find new options based on brain science. The Udall Center of Excellence will focus on the cholinergic system, which helps regulate attention and balance.
Sok Kean Khoo, a GVSU researcher, has received a $110,000 grant from the Michael J. Fox Foundation to study molecular biomarkers for Parkinson's disease. The goal is to develop a blood test for early detection and potentially improve treatment options for the incurable neurological disorder.
Researchers at Beth Israel Deaconess Medical Center identified brain networks that can help guide site selection for brain stimulation therapies. The findings suggest that stimulating sites in the same connected brain network can improve treatment outcomes across multiple neurological and psychiatric disorders.
A new study finds that people with middle-age migraines are more likely to develop Parkinson's disease and other movement disorders. Those with migraine with aura face a higher risk, with women also being more prone to a family history of the condition.
Research suggests that a high-fat diet can accelerate neurological symptoms in mice genetically predisposed to Parkinson's disease. This diet also causes damage in the brain and affects glucose and insulin regulation.
Baicalin inhibits iron accumulation after substantia nigra injury by down-regulating divalent metal transporter 1 and increasing ferroportin 1 expression. This study suggests baicalin as a potential therapeutic agent for Parkinson's disease prevention.
Researchers at Duke Medicine report that implanting deep brain stimulation devices poses no greater risk of complications to older patients with Parkinson's disease. In a study analyzing over 1,750 patients, the team found that increasing age did not significantly affect overall complication rates.
A recent study analyzing data from over 1,700 patients found that the complication risk of deep brain stimulation (DBS) is similar for both older and younger Parkinson disease patients. The results suggest that age should no longer be a rigid exclusion criterion for DBS candidates.
A new Penn Medicine study found that dopamine replacement therapy is associated with an increase in impulse control disorders and excessive daytime sleepiness in newly diagnosed Parkinson's disease patients. In contrast, fatigue improved with dopamine therapy, but depression remained undertreated.
Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease by modulating neurotransmitter signaling in the corpus striatum. This finding suggests a potential new treatment for this debilitating condition.
Researchers at Max Planck Institute show that supplying D-lactate or glycolate, two products of the gene DJ-1, can restore mitochondrial activity and prevent neuron degeneration in Parkinson's disease. These substances may also have a general role in protecting cells from decline.
Researchers found that naltrexone reduced symptoms of compulsive gambling and other behaviors in PD patients. The medication may help alleviate these issues due to dopamine agonist treatment, not necessarily a result of the disease itself.
Researchers analyzed data from over 18,000 patients to find more than two dozen genetic risk factors involved in Parkinson's disease, including six previously unknown. The study confirms that the more variants a person has, the greater their risk of developing the disorder.
Researchers at Emory University School of Medicine found that XPro1595 can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease. The drug targets tumor necrosis factor, a critical inflammatory signaling molecule, and showed benefits when administered by subcutaneous injection.
Researchers at Albert Einstein College of Medicine are developing a drug discovery project targeting Parkinson's disease using a newly identified target and chaperone-mediated autophagy. The goal is to develop a prototype drug that can treat the underlying cause of the disease.
Researchers have identified a distinct neurological profile associated with patients who respond favorably to sham surgery, but not those who are part of the placebo group. This new finding may help better identify efficacious treatments and limit the impact of placebo effects in clinical trials.
Researchers at The Feinstein Institute for Medical Research have identified a brain network that measures placebo effects in Parkinson's disease patients. This breakthrough discovery has the potential to improve the accuracy of clinical trials by excluding subjects who are more likely to experience placebo effects.
A new Tel Aviv University study confirms that Parkinson's sufferers exhibit greater creative energy than healthy individuals. Researchers found that Parkinson's patients offered more original answers and thoughtful interpretations during testing.
Researchers found that ground cinnamon can reverse biomechanical changes in mice with Parkinson's disease by protecting neurons and normalizing neurotransmitter levels. Cinnamon is metabolized into sodium benzoate, an FDA-approved drug used to treat hepatic metabolic defects.
A study published in Neurology found that brisk walking improved motor function, mood, and tiredness by up to 15%, as well as increased aerobic fitness and gait speed. Participants who walked for 45 minutes, three times a week, over six months showed significant improvements in their symptoms.
Researchers have gained unprecedented insight into the NMDA receptor, a key player in learning and memory. The new 3D model provides vital clues for developing drugs to combat neurological diseases such as Alzheimer
Scientists have identified a genetic change that impairs protein transport in cells, potentially leading to nerve cell loss and Parkinson's disease. A VPS35 gene mutation is linked to the disease, affecting cargo proteins and their correct destinations.
A self-repairing mechanism known as neurogenesis partially counteracts neuronal loss in neurodegenerative diseases. Newborn neurons generated in the dentate gyrus integrate into brain circuitry, maintaining some functions at early stages of disease progression.
Researchers at San Raffaele Scientific Institute developed a new method to convert fibroblasts into neurons, which improved motor function in rodents with parkinsonism. The study used technology that allowed the neurons to express engineered proteins and respond to specific drugs.
Researchers discovered that increased VMAT2 levels led to enhanced dopamine neurotransmission and protection from a neurotoxin. The study found improved outcomes on anxiety, depressive behaviors, movement, and protection from MPTP, a chemical causing Parkinson's disease-related damage.
A team of researchers from the University of Pennsylvania School of Medicine has developed new cell culture and mouse models to test immunotherapy for Parkinson's disease. By targeting distorted alpha-synuclein proteins, they prevented pathology development and reversed some effects of existing disease.
Researchers at the University of Oxford have developed a simple and quick MRI technique that can detect people with early-stage Parkinson's disease with 85% accuracy. The new approach uses resting-state fMRI to analyze brain connectivity in the basal ganglia, identifying those who are at risk before symptoms appear.
A new trial has found that levodopa is better than newer treatments for Parkinson's disease patients, particularly in terms of mobility and quality of life. The study, the largest ever performed on PD treatment, showed small but persistent benefits of starting treatment with levodopa.
Scientists found a strong association between REM sleep disturbance and the development of progressive brain diseases like Parkinson's and dementia. Longitudinal imaging data showed decreased dopamine transporter density in patients with REM sleep disorder, which marked the first hints of Parkinson's disease.
Researchers from Penn Medicine will present on the latest insights into Parkinson's disease, including new animal models that recapitulate alpha-synuclein pathologies. The findings highlight the complexity of the disease and potential avenues for treatment.
Researchers at McLean Hospital have found that transplanted fetal dopamine cells can remain healthy and functional for up to 14 years in patients with Parkinson's disease. The discovery could lead to new therapies using stem cells grown in labs, reducing symptoms and the need for dopamine replacement drugs.
A Rice University researcher is rebooting 'deep brain stimulation' technology to treat Parkinson's disease and other neurological disorders. The new technique uses embedded processors and real-time analytics to optimize results, potentially increasing effectiveness for a third of patients.
A $26 million research project employs advanced technology to understand and treat psychiatric disorders by analyzing brain networks. The project aims to develop neural stimulation therapies to 'unlearn' detrimental signaling patterns, potentially eliminating symptoms.
Researchers have discovered a new treatment that targets the versatile Sigma-1 receptor, improving motor function and reducing inflammation in mice with Parkinson's-like conditions. The results suggest that early activation of this protein could protect brain cells against dopamine loss and associated neural damage.
Researchers at the University of York have developed a sensitive test to detect neurological changes before degeneration occurs. The technique, which uses fruit flies, has shown promise in reducing visual signals and preventing abnormal changes.
Researchers investigated the Pael-R gene's involvement in rotenone-induced Parkinson's disease model cells using RNA interference. The study found that Pael-R expression decreased after treatment, but apoptosis and survival rates did not differ significantly between groups.
Researchers found that Compound Formula Rehmannia modulates neurotransmitter signaling to alleviate levodopa-induced dyskinesia in Parkinson's patients. This traditional Chinese medicine compound showed promise as a potential treatment for the debilitating condition.
Researchers have identified a new and accurate test for Parkinson's disease using 3T MRI scanning technology, known as the 'swallow tail' appearance of the healthy nigrosome. This sign is absent in Parkinson's disease, making it a potential diagnostic tool for clinicians.
Studies by Penn neurologists investigate the potential of statin use and estrogen to delay Parkinson's onset, with promising findings. Telemedicine is also shown to improve access to specialty care for patients with Parkinson's disease.
Oligomers are identified as the enemy that kills nerve cells and causes symptoms of Parkinson's disease. The study reveals two types of oligomers with different degrees of flexibility, which can link up to inhibit fibril formation.
Researchers at Plymouth University will use drug and gene therapies to test whether altering mitochondrial fission or fusion improves dopamine-producing nerve cells in experimental models of Parkinson's Disease. The goal is to identify a potential new therapeutic strategy for this brain disorder, potentially slowing disease progress an...
Researchers at Michigan State University have developed a promising new treatment for Parkinson's disease using a molecular tweezer that prevents protein aggregation. The molecule, CLR01, speeds up protein reconfiguration and has shown success in slowing the first step of aggregation, paving the way for clinical trials.
A study published in Psychiatry Research found that dopamine replacement therapy commonly used to treat motor symptoms of Parkinson's disease was associated with a decline in cognitive performance among depressed Parkinson patients. Mood in depressed Parkinson's patients was also worse while on dopaminergic medications.
Researchers propose that Parkinson's disease could be linked to the immune system attacking healthy neurons, potentially leading to new treatments. The study found that certain neurons display antigens, which are recognized by T-cells and can kill them, raising hopes for a new understanding of the disease.
Researchers at Griffith University's Eskitis Institute have developed a new technique for discovering natural compounds with therapeutic potential. The new screening process involves nuclear magnetic resonance (NMR) spectroscopy and has identified a potential lead in the fight against Parkinson's disease.
A study published in Cell identifies a biological process that triggers a particular form of Parkinson's disease, leading to degeneration of dopamine-producing nerve cells. The research, led by Johns Hopkins Medicine, has shed light on the origins of Parkinson's disease and may lead to new treatments.
A study funded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke found that mutations in the LRRK2 gene may cause excessive protein production, leading to cell death. This could provide a new target for monitoring Parkinson's disease and developing therapies.
Researchers at Newcastle University are investigating Google Glass as an assistive aid to help people with Parkinson's retain their independence. The technology is voice-operated and linked to the internet, providing discreet prompts to support key behaviours typical of Parkinson's.
A $16 million phase III study of isradipine as a potential neuroprotective agent in Parkinson's disease will be conducted at 56 sites in North America. Researchers aim to delay disease progression by protecting dopamine-producing neurons from toxicity.
Researchers analyze baker's yeast to uncover key features in cellular development linked to diseases such as Parkinson's and cancer. The study reveals a precise cellular role for DJ-1 family proteins, which may provide new insight into mechanisms contributing to these conditions.
Researchers at the University of Dundee have identified a critical chemical messenger that protects brain cells against Parkinson's disease. The discovery of phospho-ubiquitin suggests it may be possible to develop drugs to switch on Parkin enzyme by mimicking this molecule, offering new avenues for treatment.
Researchers uncover molecular mechanism behind Parkinson's disease, linking faulty energy production to the Pink1 gene. Correcting this defect may hold promise for treating the condition.
Parkinson's patients without dementia show impaired ability to learn new information, but not recall or recognition of previously learned material. This study suggests that improving new learning is crucial for cognitive rehabilitation interventions.
A recent study published in Neural Regeneration Research reveals that alpha-synuclein can have neuroprotective effects on dopaminergic neurons at very low concentrations. The findings suggest that extracellular alpha-synuclein may enhance neuronal survival via the Akt pathway, challenging previous views of its role in Parkinson's disease.
Researchers found that higher cerebrospinal fluid alpha-synuclein levels predict faster cognitive loss in Parkinson's disease, but not motor symptoms. The study, published in the American Journal of Pathology, offers new insights into PD pathology and potential management strategies.